BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival (OS) and/or progression free survival (PFS) over chemotherapy and have been approved for the treatment of BRAF-mutated metastatic melanoma. Here, BRAF is linked to metastatic melanoma.